RIA
EVFM

RPG Investment Advisory’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

RPG Investment Advisory’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14
Closed -$1K – 442
2017
Q2 		$1K Buy
+14
New +$2.45K ﹤0.01% 294

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCG
Ceeto Capital Group Coral Gables, Florida $326M AUM 24.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAS
WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return

RPG Investment Advisory's EVFM Position: Q3 2017 in Review

RPG Investment Advisory sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2017, closing a stake of 14 shares — an estimated $1K sold.

RPG Investment Advisory first reported a position in EVFM in Q2 2017 and held it in 1 quarter. The position peaked at $1K in Q2 2017. 11 funds tracked by Wall St. Rank hold EVFM as of Q3 2017.

  • RPG Investment Advisory reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • RPG Investment Advisory sold 14 Evofem Biosciences, Inc. Common Stock shares in Q3 2017, an estimated $1K.
  • RPG Investment Advisory first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • RPG Investment Advisory's Evofem Biosciences, Inc. Common Stock position peaked at $1K in Q2 2017.
  • 11 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2017.

Based on RPG Investment Advisory's 13F filing for Q3 2017, filed 5 Feb 2019.